- Home
- EXEL
EXEL
Exelixis Inc.
as 09-18-2025 12:18pm EST
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 10.4B | IPO Year: | 2000 |
| Target Price: | $44.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.08 | EPS Growth: | 81.76 |
| 52 Week Low/High: | $25.17 - $49.62 | Next Earning Date: | 10-28-2025 |
| Revenue: | $2,230,005,000 | Revenue Growth: | 10.73% |
| Revenue Growth (this year): | 9.19% | Revenue Growth (next year): | 12.54% |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
The Fly
a day ago
Netflix upgraded, Five Below initiated: Wall Street's top analyst calls
MT Newswires
2 days ago
Adagene Expands Agreement With Exelixis For SAFEbody Technology Platform; Adagene Shares Up Pre-Bell
GlobeNewswire
2 days ago
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Zacks
10 days ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Insider Monkey
12 days ago
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D
Insider Monkey
13 days ago
Exelixis, Inc. (EXEL): A Bull Case Theory
Simply Wall St.
a month ago
Is Exelixis Still Attractive After Recent 13% Pullback and Strong Cash Flow Growth?
Zacks
a month ago
Will EXEL's Share Repurchase Program Boost Value for Investors?
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.